SEARCH

SEARCH BY CITATION

References

  • 1
    Ryder SD, Irving WL, Jones DA, et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004; 53: 4515.
  • 2
    Strader DB, Wright T, Thomas DL, et al. American Association for the Study of Liver Diseases practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 114771.
  • 3
    Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 51724.
  • 4
    Alric L, Duffaut M, Selves J, et al. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. J Hepatol 2001; 35: 2728.
  • 5
    Arif A, Levine RA, Sanderson SO, et al. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci 2003; 48: 142530.
  • 6
    Pockros PJ, Carithers R, Desmond P, et al. , for the PEGASYS® International Study Group. Efficacy and safety of two-dose regimens of peginterferon alfa-2a compared with interferon alfa-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 2004; 99: 1298305.
    Direct Link:
  • 7
    Poynard T, McHutchison J, Manns M, et al. , for the PEG-FIBROSIS Project Group. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 130313.
  • 8
    Cammà C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39: 33342.
  • 9
    Everson GT. Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Rev Gastroenterol Disord 2004; 4 (Suppl. 1): S318.
  • 10
    Sobesky R, Mathurin P, Charlotte F, et al. , for the Multivirc Group. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999; 116: 37886.
  • 11
    Rubbia-Brandt L, Fabris P, Paganin S, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53: 40612.
  • 12
    Ratziu V, Trabut J-B, Poynard T. Fat, diabetes, and liver injury in chronic hepatitis C. Curr Gastroenterol Rep 2004; 6: 229.
  • 13
    Ortiz V, Berenguer M, Rayón JM, et al. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002; 97: 240814.
    Direct Link:
  • 14
    McCaughan GW, George J. Fibrosis progression in chronic hepatitis C virus infection. Gut 2004; 53: 31821.
  • 15
    Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 1695704.
  • 16
    Myers RP, Hilsden RJ, Lee SS. Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C. J Viral Hepat 2001; 8: 24955.
  • 17
    Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002; 97: 7006.
    Direct Link:
  • 18
    Reddy KR, Hoofnagle JH, Tong MJ, et al. , for the Consensus Interferon Study Group. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999; 30: 78793.
  • 19
    Asselah T, Rubbia-Brandt L, Marcellin P, et al. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55: 12330.
  • 20
    Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 163642.
  • 21
    Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 37081.
  • 22
    Heathcote EJ, Shiffman ML, Cooksley WGE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 167380.
  • 23
    Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 4315.
  • 24
    Bedossa P, Poynard T, for the METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 28993.
  • 25
    Germer JJ, Rys PN, Thorvilson JN, et al. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999; 37: 262530.
  • 26
    Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117: 116472.
  • 27
    Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 42533.
  • 28
    Layden TJ, Layden JE, Reddy KR, et al. Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. J Viral Hepat 2002; 9: 3349.
  • 29
    Fontana RJ, Everson GT, Tuteja S, et al. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clin Gastroenterol Hepatol 2004; 2: 18397.
  • 30
    Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alfa is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 57987.
  • 31
    Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 67784.
  • 32
    Arase Y, Ikeda K, Suzuki F, et al. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol 2007; 79: 148590.
  • 33
    Arase Y, Ikeda K, Suzuki F, et al. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol 2007; 79: 1095102.
  • 34
    Rincon D, Ripoll C, Lo Iacono O, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006; 101: 226974.
    Direct Link:
  • 35
    Huang JF, Yu ML, Lee CM, et al. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan. Aliment Pharmacol Ther 2007; 25: 102937.
  • 36
    Fartoux L, Degos F, Trepo C, et al. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol 2007; 5: 5027.
  • 37
    Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial. Hepatology 2007; 46: 290A (abstract LB1).
  • 38
    Mallat A, Preaux AM, Blazejewski S, et al. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995; 21: 100310.
  • 39
    Knittel T, Muller L, Saile B, et al. Effect of tumour necrosis factor-alfa on proliferation, activation and protein synthesis of rat hepatic stellate cells. J Hepatol 1997; 27: 106780.
  • 40
    Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 166672.